Skip to content

Startup & venture capital news

Sava raises USD 36m Series B

Ascensia Diabetes Care leads funding and a European distribution partnership

By /

LinkedInX
Sava Technologies team seated on outdoor steps.
Source: EU-Startups.

Sava announced a USD 36 million Series B on 9 October 2026, led by Ascensia Diabetes Care. Imperial researchers Renato Circi and Rafaël Michali founded the London company to develop wearable glucose microsensors. The financing is accompanied by an Ascensia partnership supporting its planned European market entry. Sava's work centres on a sensing platform for diabetes care, combining research in miniature devices with the requirements of a medical product. The investment brings a corporate healthcare partner into the company's next stage. Its story links university-origin technology, specialist founders and a distribution relationship relevant to bringing the proposed product to users.

Keep reading

More Funding

All stories